Denmark
· Delayed Price · Currency is DKK Novozymes Statistics
Total Valuation
Novozymes has a market cap or net worth of DKK 252.97 billion. The enterprise value is 263.78 billion.
| Market Cap | 252.97B |
| Enterprise Value | 263.78B |
Important Dates
The next estimated earnings date is Thursday, August 21, 2025.
| Earnings Date | Aug 21, 2025 |
| Ex-Dividend Date | Apr 4, 2025 |
Share Statistics
Novozymes has 519.44 million shares outstanding. The number of shares has decreased by -8.56% in one year.
| Current Share Class | 465.70M |
| Shares Outstanding | 519.44M |
| Shares Change (YoY) | -8.56% |
| Shares Change (QoQ) | +68.44% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 31.49% |
| Float | 346.43M |
Valuation Ratios
The trailing PE ratio is 41.33 and the forward PE ratio is 31.11. Novozymes's PEG ratio is 3.06.
| PE Ratio | 41.33 |
| Forward PE | 31.11 |
| PS Ratio | 8.36 |
| PB Ratio | 3.02 |
| P/TBV Ratio | 25.05 |
| P/FCF Ratio | 55.45 |
| P/OCF Ratio | 35.70 |
| PEG Ratio | 3.06 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.03, with an EV/FCF ratio of 57.82.
| EV / Earnings | 77.12 |
| EV / Sales | 8.71 |
| EV / EBITDA | 30.03 |
| EV / EBIT | 38.54 |
| EV / FCF | 57.82 |
Financial Position
The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.15.
| Current Ratio | 1.66 |
| Quick Ratio | 1.03 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 1.44 |
| Debt / FCF | 2.78 |
| Interest Coverage | 11.41 |
Financial Efficiency
Return on equity (ROE) is 6.97% and return on invested capital (ROIC) is 7.25%.
| Return on Equity (ROE) | 6.97% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 7.25% |
| Return on Capital Employed (ROCE) | 6.64% |
| Revenue Per Employee | 2.86M |
| Profits Per Employee | 323,219 |
| Employee Count | 10,582 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Novozymes has paid 1.17 billion in taxes.
| Income Tax | 1.17B |
| Effective Tax Rate | 25.42% |
Stock Price Statistics
The stock price has increased by +18.46% in the last 52 weeks. The beta is 0.54, so Novozymes's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +18.46% |
| 50-Day Moving Average | 436.39 |
| 200-Day Moving Average | 429.55 |
| Relative Strength Index (RSI) | 67.25 |
| Average Volume (20 Days) | 610,156 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novozymes had revenue of DKK 30.27 billion and earned 3.42 billion in profits. Earnings per share was 11.78.
| Revenue | 30.27B |
| Gross Profit | 15.96B |
| Operating Income | 6.88B |
| Pretax Income | 4.59B |
| Net Income | 3.42B |
| EBITDA | 8.82B |
| EBIT | 6.88B |
| Earnings Per Share (EPS) | 11.78 |
Balance Sheet
The company has 1.86 billion in cash and 12.67 billion in debt, giving a net cash position of -10.81 billion or -20.82 per share.
| Cash & Cash Equivalents | 1.86B |
| Total Debt | 12.67B |
| Net Cash | -10.81B |
| Net Cash Per Share | -20.82 |
| Equity (Book Value) | 83.78B |
| Book Value Per Share | 179.71 |
| Working Capital | 5.79B |
Cash Flow
In the last 12 months, operating cash flow was 7.09 billion and capital expenditures -2.52 billion, giving a free cash flow of 4.56 billion.
| Operating Cash Flow | 7.09B |
| Capital Expenditures | -2.52B |
| Free Cash Flow | 4.56B |
| FCF Per Share | 8.78 |
Margins
Gross margin is 52.73%, with operating and profit margins of 22.72% and 11.30%.
| Gross Margin | 52.73% |
| Operating Margin | 22.72% |
| Pretax Margin | 15.15% |
| Profit Margin | 11.30% |
| EBITDA Margin | 29.12% |
| EBIT Margin | 22.72% |
| FCF Margin | 15.07% |
Dividends & Yields
This stock pays an annual dividend of 6.19, which amounts to a dividend yield of 1.27%.
| Dividend Per Share | 6.19 |
| Dividend Yield | 1.27% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 54.46% |
| Buyback Yield | 8.56% |
| Shareholder Yield | 9.84% |
| Earnings Yield | 1.35% |
| FCF Yield | 1.80% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 28, 2011. It was a forward split with a ratio of 5.
| Last Split Date | Nov 28, 2011 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Novozymes has an Altman Z-Score of 5.71 and a Piotroski F-Score of 3.
| Altman Z-Score | 5.71 |
| Piotroski F-Score | 3 |